Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Legal, Legislative Quest To Expand Off-Label Part D Coverage Continues

Executive Summary

The Medicare Rights Center is continuing a lawsuit seeking to expand coverage for off-label indications under the Medicare Part D prescription drug benefit after helping a beneficiary gain coverage of a drug to treat ovarian cancer

You may also be interested in...

Broader Medicare Part D Coverage For Off-Label Drug Use Gets Boost From Court Decision

New York federal court decides three-year-old case brought by the Medicare Rights Center against the federal government.

Part D Off-Label Coverage Should Not Be Limited To Compendia Lists – Lawsuit

Medicare Part D drug plans should be able to consider a variety of evidence supporting off-label uses of drugs, not just the standard medical compendia list of accepted indications, a lawsuit challenging HHS' interpretation of congressional directives on this issue argues

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts